Last updated: March 1, 2026
What is the drug associated with NDC 64380-0184?
NDC 64380-0184 corresponds to a specific formulation within the scope of pharmaceutical products. Based on available public records, this NDC is associated with Bexagliflozin—a sodium-glucose co-transporter 2 (SGLT2) inhibitor developed for the treatment of type 2 diabetes mellitus.
What is the market landscape for Bexagliflozin?
Market size and growth potential
The incretin and SGLT2 inhibitor segments dominate the oral diabetes treatment market. The global market for SGLT2 inhibitors was valued at approximately $12 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 12% through 2028 [1].
Key competitors
Major approved SGLT2 inhibitors include:
- dapagliflozin (Farxiga)
- empagliflozin (Jardiance)
- ertugliflozin (Steglatro)
- canagliflozin (Invokana)
Bexagliflozin has not yet gained full regulatory approval but is under development or pending submission in multiple regions.
Market penetration considerations
Bexagliflozin's market entry depends on factors such as clinical efficacy, safety profile, pricing, and physician acceptance. Early data suggest comparable efficacy to existing agents with potential advantages in safety or dosing. Its success hinges on demonstrated benefits over current standards of care.
What are current price benchmarks?
Existing SGLT2 inhibitor pricing
Approximate wholesale acquisition costs (WAC) per month are:
- Dapagliflozin (Farxiga): $420
- Empagliflozin (Jardiance): $410
- Canagliflozin (Invokana): $380
- Eretugliflozin (Steglatro): $390
Generic versions of some agents reduce prices slightly. Pricing models focus on annual treatment costs of $4,800 to $5,000 per patient, varying by region and insurance coverage.
Projected pricing for Bexagliflozin
Given the competitive landscape, initial pricing is anticipated similar to existing monotherapies, ranging from $400 to $500 per month. Premium positioning, such as improved safety or dosing benefits, could sustain higher pricing initially.
Price projections over five years:
| Year |
Estimated Monthly Price |
Rationale |
| Year 1 |
$470 |
Launch price aligned with premium options |
| Year 2 |
$450 |
Market competition begins to influence price |
| Year 3 |
$430 |
Price stabilization amid increased competition |
| Year 4 |
$410 |
Potential generic entry or biosimilar influence |
| Year 5 |
$390 |
Price reduction following patent expiry or biosimilar entrance |
What regulatory and reimbursement factors influence market access?
- FDA approval: Success depends on demonstrating superiority or non-inferiority to existing agents.
- Pricing negotiations: Payers may negotiate discounts, especially if clinical benefits are marginal.
- Patent landscape: Patent expiry or challenges could bring generics shortly after launch, pressuring prices downward.
What is the likely impact of biosimilar entry?
While biosimilars are less common for small molecules like Bexagliflozin, generics or biosimilar competitors could enter within 5-7 years post-launch, driving prices down by 30-60% depending on market elasticity.
Summary of Key Market Drivers
- Growth driven by increasing diabetes prevalence worldwide.
- Competition from established SGLT2 inhibitors.
- Pricing influenced by clinical differentiation, regulatory success, and patent status.
- Entry timing impacts initial pricing and subsequent reductions.
Final remarks
Bexagliflozin’s market potential depends heavily on clinical differentiation and regulatory approval timing. The initial price point is expected near existing SGLT2 inhibitors, with reductions possible during lifecycle management.
Key Takeaways
- NDC 64380-0184 likely refers to Bexagliflozin, an SGLT2 inhibitor targeting type 2 diabetes.
- The global market for SGLT2 inhibitors exceeds $12 billion, with a CAGR of 12% projected to 2028.
- Entry price estimates hover around $470/month initially, declining as generic competition emerges.
- Market growth depends on clinical differentiation, efficacy, safety, and reimbursement policies.
- Patent cliffs and biosimilar entry could reduce prices by up to 60% over 5-7 years post-launch.
FAQs
1. When is Bexagliflozin expected to reach the market?
Regulatory submissions are ongoing in select regions. Approval timelines vary, with potential launch within 1-3 years if regulatory hurdles are cleared.
2. How does Bexagliflozin differentiate from existing SGLT2 inhibitors?
Clinical trial data suggest differences in safety profile and dosing frequency, but definitive advantages remain under review.
3. What is the impact of generic SGLT2 inhibitors on pricing?
Generic availability can reduce prices by roughly 50-60%, impacting margins and market share.
4. Are there regional variations in pricing?
Yes, pricing varies significantly, influenced by healthcare system policies, insurance coverage, and negotiated discounts.
5. Will Bexagliflozin face regulatory or patent hurdles?
Potential patent expiries or legal challenges may accelerate generic entry, affecting long-term pricing strategies.
References
[1] MarketsandMarkets. (2022). SGLT2 Inhibitors Market by Drug Type, Application, and Region.
